Early palliative care of non-small cell lung cancer in the context of immunotherapy.
early palliative care
glucorticosterois
immunotherapy
lung cancer
opioids
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
23
07
2020
accepted:
06
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
ppublish
Résumé
The most common cause of mortality due to malignant neoplasms in the general population around the world is lung cancer. In the last 10 years, there has been an enormous improvement in the treatment of this disease, mainly due to the immunotherapy that activates the immune system to fight cancer. Patients with metastatic non-small cell lung cancer are a special group of patients requiring not only cancer treatment but also considerable support in the treatment of cancer-related problems, as well as comorbidities. Early palliative care is important in this area. In addition, there is certain evidence that medicines most commonly administered in palliative care may lower the efficacy of immunotherapy. The present review article compares information on the prolonging of life after early hospice care, which has become the foundation of current standards of management in patients with metastatic lung cancer, and reports of decreased efficacy of the immunotherapy due to the administration of major palliative care medications.
Identifiants
pubmed: 33193856
doi: 10.3892/ol.2020.12259
pii: OL-0-0-12259
pmc: PMC7656105
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
396Informations de copyright
Copyright: © Pieniążek et al.
Références
Chron Respir Dis. 2013 Feb;10(1):35-47
pubmed: 23355404
Cell. 2016 Apr 7;165(2):276-87
pubmed: 27058662
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
J Palliat Med. 2013 Dec;16(12):1568-74
pubmed: 24151960
Lancet. 2014 May 17;383(9930):1721-30
pubmed: 24559581
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Ann Oncol. 2019 May;30(5):863-870
pubmed: 31987360
Nature. 2012 Sep 13;489(7415):220-30
pubmed: 22972295
JAMA. 2015 Nov 17;314(19):2017-8
pubmed: 26426830
Cancers (Basel). 2016 Sep 06;8(9):
pubmed: 27608043
J Thorac Oncol. 2019 May;14(5):793-801
pubmed: 30711649
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Cancer. 2018 Oct;102:23-30
pubmed: 30103096
Dig Dis. 2016;34(3):260-8
pubmed: 27028893
Clin Lung Cancer. 2018 Sep;19(5):441-449.e4
pubmed: 30017645
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Oncol. 2018 Jun 1;29(6):1437-1444
pubmed: 29617710
J Pain Palliat Care Pharmacother. 2007;21(4):69-76
pubmed: 18032321
J Clin Oncol. 2017 Mar 10;35(8):834-841
pubmed: 28029308
Trends Immunol. 2012 Sep;33(9):459-66
pubmed: 22677185
Transl Lung Cancer Res. 2015 Aug;4(4):327-38
pubmed: 26380174
Eur J Cancer. 2019 Jul;116:137-147
pubmed: 31195357
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
J Clin Oncol. 2020 Aug 1;38(22):2530-2542
pubmed: 32459597
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
J Thorac Oncol. 2018 Feb;13(2):194-204
pubmed: 29129758
J Clin Oncol. 2020 May 10;38(14):1505-1517
pubmed: 32150489
J Pain Palliat Care Pharmacother. 2018 Mar;32(1):37-43
pubmed: 29737903
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
BMC Palliat Care. 2011 Sep 21;10:14
pubmed: 21936940
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Pain Res Manag. 2018 Sep 19;2018:9293704
pubmed: 30327708
J Pain Symptom Manage. 2016 Jun;51(6):1027-32
pubmed: 26948411
J Clin Oncol. 2012 Mar 10;30(8):880-7
pubmed: 22312101